Scientists at Yale School of Medicine have pinpointed two proteins that act as cellular gatekeepers, allowing a toxic protein to invade healthy neurons in Parkinson's disease. The discovery could reshape how researchers approach the illness, moving from symptom management toward blocking the disease's spread entirely.
The finding centers on alpha-synuclein, a misfolded protein that accumulates in the brains of Parkinson's patients and drives neurodegeneration. For years, researchers knew this protein moved from dying neurons to healthy ones, but the mechanism remained obscure. A study published in Nature Communications now reveals two membrane proteins, mGluR4 and NPDC1, serve as the transporters responsible for ferrying alpha-synuclein across cell barriers.
The research team, led by Stephen Strittmatter, chair of neuroscience at Yale School of Medicine, engineered 4,400 groups of cells, each displaying a different surface protein. They exposed these engineered cells to misfolded alpha-synuclein and tracked which proteins it bound to. Out of thousands tested, only 16 surface proteins interacted with the toxic protein. Among them were mGluR4 and NPDC1, both found abundantly on dopamine-producing neurons in the substantia nigra, the brain region most ravaged by Parkinson's disease.
To confirm these proteins actually transported alpha-synuclein into neurons, researchers created genetically modified mice lacking functional copies of either mGluR4 or NPDC1. Normal mice exposed to the misfolded protein developed brain accumulations and displayed Parkinson's-like symptoms. The engineered mice without these proteins showed no such decline. In separate mouse models engineered to develop Parkinson's disease naturally, removing either gene slowed symptom progression and reduced death risk.
Current Parkinson's treatments manage tremors and movement problems but do not slow the underlying disease process. Strittmatter emphasized the stakes in an aging America. About 1.1 million Americans currently live with Parkinson's disease, with nearly 90,000 new diagnoses each year. As the population ages, the burden will intensify dramatically in coming decades.
A therapy that blocks alpha-synuclein transport could work fundamentally differently from existing drugs. Instead of masking symptoms while neurons continue dying, such a treatment could arrest the cascade of cellular damage itself.
Author Jessica Williams: "If you can actually stop a neurodegenerative disease from spreading rather than just turning down the volume on its symptoms, that changes everything about how you think about treatment."
Comments